Transcend Therapeutics: Funding, Investors & Team (Sep 2026)
Transcend Therapeutics is a neuroscience-focused firm that is in the trial stages of developing the next generation of psychoactive medications for neuropsychiatric disorder. Transcend creates drugs that are affordable for a larger proportion of sick patients, including the tens of millions of people who already take psychotropic drugs. We have real-world data demonstrating that >85% of patients with PTSD and depression significantly benefited from our primary product. With ambitions to extend into depression and other indications, we have already pushed our lead chemical into a PTSD-specific Phase II research that has been approved.
Transcend Therapeutics has raised $40.0M across 1 funding round on record, the most recent a Series A of $40.0M announced in Feb 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Transcend Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Transcend Therapeutics Funding Rounds
Transcend Therapeutics Founders and Leadership Team
Contact details for the Transcend Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Transcend Therapeutics Funding Compared to Other Biotechnology Startups
Transcend Therapeutics' latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Transcend Therapeutics in Biotechnology and Waltham
Companies Similar to Transcend Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Transcend Therapeutics Funding FAQs
What does Transcend Therapeutics do?
Transcend Therapeutics is a neuroscience-focused firm that is in the trial stages of developing the next generation of psychoactive medications for neuropsychiatric disorder. Transcend creates drugs that are affordable for a larger proportion of sick patients, including the tens of millions of people who already take psychotropic drugs. We have real-world data demonstrating that >85% of patients with PTSD and depression significantly benefited from our primary product. With ambitions to extend into depression and other indications, we have already pushed our lead chemical into a PTSD-specific Phase II research that has been approved.
How much funding has Transcend Therapeutics raised?
Transcend Therapeutics has raised $40.0M across 1 round on record. The most recent is a Series A of $40.0M announced in Feb 2023.
When did Transcend Therapeutics last raise funding?
Transcend Therapeutics' most recent funding round on record is a Series A of $40.0M, announced in Feb 2023.
Who is the CEO of Transcend Therapeutics?
Blake Mandell is listed as CEO at Transcend Therapeutics.
Where is Transcend Therapeutics headquartered?
Transcend Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does Transcend Therapeutics have?
Transcend Therapeutics is in the 1-10 employee band.
How does Transcend Therapeutics' funding compare to other Biotechnology startups?
Transcend Therapeutics' latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Transcend Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Transcend Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.